Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.00M | 2.00M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 2.00M | 2.00M | 2.00M |
| Cost of Revenue | 0.00 | 0.00 | 1.99M | 1.99M | 1.99M |
| Gross Profit | 0.00 | 0.00 | 13.00K | 13.00K | 13.00K |
| SG&A Expenses | 9.79M | 8.48M | 8.72M | 7.17M | 6.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.52M | 14.25M | 17.09M | 15.01M | 15.67M |
| Operating Income | -14.52M | -14.25M | -15.09M | -13.01M | -13.67M |
| Income Before Tax | 220.28M | 131.82M | 75.32M | 55.74M | -22.22M |
| Income Tax Expenses | 45.41M | 21.85M | 11.31M | 11.94M | 2.01M |
| Earnings from Continuing Operations | 174.86 | 109.97 | 64.02 | 43.81 | -24.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.00K | 34.00K | 34.00K | 44.00K | 61.00K |
| Net Income | 174.87M | 110.00M | 64.05M | 43.85M | -24.16M |
| EBIT | -14.52M | -14.25M | -15.09M | -13.01M | -13.67M |
| EBITDA | -14.40M | -14.13M | -14.97M | -12.89M | -13.53M |
| EPS Basic | 4.23 | 2.64 | 1.52 | 1.04 | -0.60 |
| Normalized Basic EPS | -0.07 | -0.06 | -0.19 | -0.13 | -0.14 |
| EPS Diluted | 4.10 | 2.57 | 1.47 | 0.99 | -0.62 |
| Normalized Diluted EPS | -0.07 | -0.06 | -0.19 | -0.13 | -0.14 |
| Average Basic Shares Outstanding | 164.47M | 165.18M | 165.63M | 165.48M | 164.62M |
| Average Diluted Shares Outstanding | 168.15M | 168.26M | 167.52M | 167.37M | 165.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 5.97% | 9.42% | -- | -- | -- |